Data as of Dec 19
| -0.095 / -1.29%|
The 3 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 9.00, with a high estimate of 11.00 and a low estimate of 6.00. The median estimate represents a +24.14% increase from the last price of 7.25.
The current consensus among 4 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.